Paloma Partners’s Abeona Therapeutics ABEO Stock Holding History

Paloma Partners’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,140	Closed	-$203K	–	1649
2018 Q4	$203K	Buy	+1,140	New	+$249K	0.01%	1054
2016 Q3	–	Sell	-1,680	Closed	-$99K	–	1796
2016 Q2	$99K	Buy	+1,680	New	+$115K	﹤0.01%	2078

Other funds holding ABEO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Paloma Partners's ABEO Position: Q1 2019 in Review

Paloma Partners sold out of Abeona Therapeutics (ABEO) in Q1 2019, closing a stake of 1,140 shares — an estimated $203K sold.

Paloma Partners first reported a position in ABEO in Q2 2016 and held it in 2 quarters. The position peaked at $203K in Q4 2018. 87 funds tracked by Wall St. Rank hold ABEO as of Q1 2019.

Paloma Partners reported no remaining Abeona Therapeutics position as of Q1 2019 after selling out during the quarter.
Paloma Partners sold 1,140 Abeona Therapeutics shares in Q1 2019, an estimated $203K.
Paloma Partners first reported a position in Abeona Therapeutics in Q2 2016 and held it in 2 quarters.
Paloma Partners's Abeona Therapeutics position peaked at $203K in Q4 2018.
87 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2019.

Based on Paloma Partners's 13F filing for Q1 2019, filed 15 May 2019.